NASDAQ$GEHC
GE HealthCare Technologies Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
GE HealthCare reported 2.17% revenue growth in Q4 2024, reaching $5.319 billion. Strong performance in Advanced Visualization Solutions and Pharmaceutical Diagnostics drove results, alongside improved operating and net margins. Adjusted earnings per share grew 22.88% year-over-year.
Headline financials
Revenue & EPS history
GE HealthCare · Revenue · Quarterly
$5.32B
Revenue by segment
GE HealthCare · $4.01B total across 4 segments · Q3 2023
- Imaging$2.64B+4.7%65.8%
- Patient Care$764M+9.0%19.1%
- Pharma Diagnostics$589M+12.8%14.7%
- Other$19M+35.7%0.5%
Forward guidance
GE HealthCare expects 2%-3% organic revenue growth in 2025, with margin expansion and adjusted EPS growth of 3%-6%. The company will continue investing in innovation and operational efficiency.
Tailwinds
- Expected 2%-3% organic revenue growth
- Adjusted EBIT margin expansion of 40-50 basis points
- Adjusted EPS growth of 3%-6%
- Sustained demand in Pharmaceutical Diagnostics and Advanced Visualization
- Investment strategy in AI and advanced diagnostics
Headwinds
- Impact of tariffs on products from China
- Ongoing market weakness in China
- Inflationary pressures on operating costs
- Higher financing costs due to interest rates
- Increasing competition in the medical diagnostics sector
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q4 2024
-0.2%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.3%
Avg return
30 days after
50%
8 / 16 earnings
Positive
+11.5%
Q4 2021
Best reaction
-12.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -12.9% | -10.9% | -8.9% | |
| Q4 2025 | +6.4% | +0.4% | -5.7% | |
| Q3 2025 | -2.7% | -6.2% | +0.7% | |
| Q1 2025 | +3.3% | +1.9% | +3.6% | |
| Q4 2024 | +8.8% | +7.9% | -4.6% | |
| Q3 2024 | +2.4% | +2.0% | -2.4% | |
| Q2 2024 | +0.9% | -1.4% | +2.6% | |
| Q1 2024 | -12.0% | -10.6% | -11.7% | |
| Q4 2021 | +11.5% | +10.8% | +26.2% | |
| Q3 2023 | +8.1% | +13.3% | +8.4% | |
| Q3 2022 | +8.1% | +13.3% | +8.4% | |
| Q2 2023 | -4.0% | -3.4% | -15.1% | |
| Q1 2023 | -8.7% | -7.3% | -9.0% | |
| Q1 2022 | -8.7% | -7.3% | -9.0% | |
| Q2 2022 | -2.3% | +0.8% | +4.4% | |
| Q4 2022 | -0.8% | +0.7% | +7.4% | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro